![](https://www.diabetesnews.com/wp-content/uploads/2014/05/o-WEIGHT-LOSS-MYTH-facebook-150x150.jpg)
The US Food and Drug Administration (FDA) recently approved a 2.4 mg/week subcutaneous dose of the GLP-1 receptor agonist semaglutide for weight loss in people who have obesity, or overweight with a related health complication. Semaglutide is already in use to treat type 2 diabetes, but the approval for this drug, to be sold under the brand name Wegovyâ„¢, is for a formulation more than double the standard dose for diabetes treatment. Read more